Analysis of the efficacy and safety of Azithromycin sequential therapy in treatment with mycoplasma pneumonia
- VernacularTitle:阿奇霉素序贯疗法治疗小儿支原体肺炎的疗效及安全性分析
- Author:
Boying WU
1
;
Zhe ZHANG
;
Hongzhen XU
Author Information
1. 宁波市鄞州人民医院儿科
- Keywords:
Mycoplasma pneumonia;
Azithromycin;
Aequential therapy;
Adverse reactions
- From:
China Modern Doctor
2014;(29):143-145
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of azithromycin sequential therapy in treatment with my-coplasma pneumonia. Methods A total of 134 cases with mycoplasma pneumonia were selected in respiratory depart-ment of our hospital during April 2012 to June 2013, and then divided into observation group and control group ac-cording to the different treatment, which received azithromycin sequential therapy and erythromycin intravenous infu-sion respectively. The clinical effects and the incidence of adverse reactions were comparatively analyzed. Results 14 d after treatment,the treatment efficiency of observation group reached 95.71%,which was significantly higher than that in control (79.69%)(P<0.05).The fading time of coughing,the fading time of crackles and rale and the time of fever descending to normal were significantly shorter than that in control (P<0.05). Meanwhile,the adverse reaction rate of the observation group, include joint pain, rash, gastrointestinal reactions, elevated serum alanine aminotransferase,were significantly lower than that in the control group (P<0.05). Conclusion Azithromycin sequential therapy have a good clinical efficacy in treatment with mycoplasma pneumonia, shorten the symptoms disappearance time and hospi-talization time and reduce toxicity,which is widely used in clinical practice.
